Werewolf Therapeutics' (HOWL) "Sell (D-)" Rating Reaffirmed at Weiss Ratings

Key Points

• Weiss Ratings has reiterated a "sell (D-)" rating for Werewolf Therapeutics (NASDAQ:HOWL), highlighting concerns over the stock's performance.
• Other analysts have mixed opinions, with JMP Securities lowering their price target from $4.00 to $3.00, while Zacks Research upgraded it from "hold" to "strong-buy."
• Werewolf Therapeutics reported an earnings per share loss of ($0.40), which is better than the expected loss of ($0.50), indicating a possible improvement in financial results.

Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report)'s stock had its "sell (d-)" rating reiterated by Weiss Ratings in a research note issued to investors on Friday,Weiss Ratings reports.

Other equities analysts have also recently issued research reports about the company. JMP Securities dropped their price target on Werewolf Therapeutics from $4.00 to $3.00 and set a "market outperform" rating on the stock in a research report on Thursday, August 21st. Bank of America dropped their price target on Werewolf Therapeutics from $9.00 to $8.00 and set a "buy" rating on the stock in a research report on Monday, August 25th. Zacks Research upgraded Werewolf Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Thursday, October 16th. Finally, Citigroup reissued a "buy" rating on shares of Werewolf Therapeutics in a research note on Monday, August 25th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $8.00.

Werewolf Therapeutics Stock Performance

HOWL stock traded up $0.20 during trading on Friday, hitting $1.77. The company had a trading volume of 1,057,139 shares, compared to its average volume of 482,831. The firm has a market cap of $80.94 million, a PE ratio of -1.08 and a beta of 0.76. Werewolf Therapeutics has a 1-year low of $0.60 and a 1-year high of $3.26. The firm has a 50-day moving average price of $1.58 and a 200-day moving average price of $1.27. The company has a quick ratio of 5.30, a current ratio of 5.30 and a debt-to-equity ratio of 0.60.

Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.10. On average, analysts expect that Werewolf Therapeutics will post -1.56 earnings per share for the current year.

Institutional Investors Weigh In On Werewolf Therapeutics

Institutional investors have recently modified their holdings of the company. Vontobel Holding Ltd. purchased a new stake in shares of Werewolf Therapeutics during the 1st quarter worth approximately $34,000. Charles Schwab Investment Management Inc. boosted its stake in shares of Werewolf Therapeutics by 33.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company's stock worth $93,000 after acquiring an additional 23,852 shares in the last quarter. MPM Asset Management LLC boosted its stake in shares of Werewolf Therapeutics by 0.6% during the 1st quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company's stock worth $4,189,000 after acquiring an additional 25,688 shares in the last quarter. Nuveen LLC purchased a new stake in shares of Werewolf Therapeutics during the 1st quarter worth approximately $71,000. Finally, MPM Bioimpact LLC boosted its stake in shares of Werewolf Therapeutics by 0.9% during the 1st quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company's stock worth $2,341,000 after acquiring an additional 20,799 shares in the last quarter. Hedge funds and other institutional investors own 64.84% of the company's stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.